Published in:
Open Access 01-12-2018 | Guideline
Development process of a consensus-driven CONSORT extension for randomised trials using an adaptive design
Published in: BMC Medicine | Issue 1/2018
Login to get accessAbstract
Background
Adequate reporting of adaptive designs (ADs) maximises their potential benefits in the conduct of clinical trials. Transparent reporting can help address some obstacles and concerns relating to the use of ADs. Currently, there are deficiencies in the reporting of AD trials. To overcome this, we have developed a consensus-driven extension to the CONSORT statement for randomised trials using an AD. This paper describes the processes and methods used to develop this extension rather than detailed explanation of the guideline.
Methods
We developed the guideline in seven overlapping stages:
1)
Building on prior research to inform the need for a guideline;
2)
A scoping literature review to inform future stages;
3)
Drafting the first checklist version involving an External Expert Panel;
4)
A two-round Delphi process involving international, multidisciplinary, and cross-sector key stakeholders;
5)
A consensus meeting to advise which reporting items to retain through voting, and to discuss the structure of what to include in the supporting explanation and elaboration (E&E) document;
6)
Refining and finalising the checklist; and
7)
Writing-up and dissemination of the E&E document.
The CONSORT Executive Group oversaw the entire development process.
Results
Delphi survey response rates were 94/143 (66%), 114/156 (73%), and 79/143 (55%) in rounds 1, 2, and across both rounds, respectively. Twenty-seven delegates from Europe, the USA, and Asia attended the consensus meeting. The main checklist has seven new and nine modified items and six unchanged items with expanded E&E text to clarify further considerations for ADs. The abstract checklist has one new and one modified item together with an unchanged item with expanded E&E text. The E&E document will describe the scope of the guideline, the definition of an AD, and some types of ADs and trial adaptations and explain each reporting item in detail including case studies.
Conclusions
We hope that making the development processes, methods, and all supporting information that aided decision-making transparent will enhance the acceptability and quick uptake of the guideline. This will also help other groups when developing similar CONSORT extensions. The guideline is applicable to all randomised trials with an AD and contains minimum reporting requirements.